| Lisa M Radziwanowicz, MCD CCC SLP | |
|
20420 68th Ave W, Lynnwood, WA 98036-7405 | |
| (425) 431-1069 | |
| Not Available |
| Full Name | Lisa M Radziwanowicz |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 20420 68th Ave W, Lynnwood, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083963789 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lisa M Radziwanowicz, MCD CCC SLP 20420 68th Ave W, Lynnwood, WA 98036-7405 Ph: () - | Lisa M Radziwanowicz, MCD CCC SLP 20420 68th Ave W, Lynnwood, WA 98036-7405 Ph: (425) 431-1069 |
News Archive
The QT interval is part of the heart's electrical cycle as measured by ECG, and represents the electrical depolarization and repolarization of the ventricles. Lengthened intervals indicate dysfunction in the heart beat and are liable to lead to a five-fold increase in the risk of sudden death from heart failure.
Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, announced today that it has completed a $12 million Series A financing. The round was led by Third Rock Ventures and included Pfizer Venture Investments. Proceeds from the financing will be used to continue advancing Ablexis' proprietary AlivaMab Mouse transgenic mouse platform for the discovery of human therapeutic antibodies.
Schizophrenia patients, their families, and psychiatrists differ significantly in their perception of remission, study results show.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
› Verified 3 days ago
Carole Barbara Scandella, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20420 68th Ave W, Lynnwood, WA 98036 Phone: 425-431-7180 | |
Robert Thomas Morton, M.S., SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20818 44th Ave W # 270-b, Lynnwood, WA 98036 Phone: 425-672-9219 | |
Charlotte U Richardson, MS, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20420 68th Ave W, Lynnwood, WA 98036 Phone: 425-431-1050 | |
Mrs. Ruth Eng, MSPA, CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20420 68th Ave W, Lynnwood, WA 98036 Phone: 425-431-1079 | |
Rachelle Zadigian, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20420 68th Ave W, Lynnwood, WA 98036 Phone: 425-431-7000 | |
Aleksey Brooke Green, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 18905 33rd Ave W Ste 109, Lynnwood, WA 98036 Phone: 425-361-7046 Fax: 425-249-3525 |